Boehringer Ingelheim has introduced LENZELTA®, a novel vaccine designed to significantly reduce the incidence and severity of clinical mastitis in dairy cows and heifers. Administered in two doses during the dry-off period, this vaccine targets the two primary pathogens responsible for mastitis, Staphylococcus aureus and Escherichia coli, providing a proactive approach to herd health management.

The significance of LENZELTA® lies in its ability to offer early onset of immunity and prolonged protection, lasting up to six months, which is critical during the high-risk period surrounding calving. Mastitis is a pervasive issue that not only compromises cow health but also leads to substantial economic losses in dairy production. By integrating LENZELTA® into existing herd management practices, veterinarians and farmers can enhance udder health, improve milk quality and quantity, and ultimately mitigate the economic burden associated with mastitis.

The introduction of LENZELTA® marks a potential shift in the management of mastitis, emphasizing a preventive strategy at a crucial juncture in the lactation cycle. This vaccine not only provides a practical tool for veterinarians but also empowers farmers by reducing the prevalence and impact of mastitis infections. As it becomes available in several EU countries starting in April 2026, LENZELTA® could redefine standards in mastitis prevention and contribute to more sustainable dairy farming practices.

Source: globenewswire.com